Medtronic extends Activa therapy to dystonia:
This article was originally published in Clinica
Executive Summary
Medtronic has gained US approval to expand the use of its Activa brain stimulation technology to the treatment of a neurological movement disorder called dystonia. The device, approved under the agency's Humanitarian Device Exemption regulations for treating the most severe and disabling forms of the condition, is already cleared for treating symptoms of advanced Parkinson's disease and essential tremor. Medtronic says that every year in the US around 2,400 patients are diagnosed with forms of dystonia that may be treated with the Activa device. European approval for the dystonia indication is expected to come later this year.